Currently out of the existing stock ratings of Vamil Divan, 229 are a BUY (64.69%), 111 are a HOLD (31.36%), 14 are a SELL (3.95%).

Vamil Divan

Work Performance Price Targets & Ratings Chart

Analyst Vamil Divan, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 64.67% that have a potential upside of 29.09% achieved within 252 days.

Vamil Divan’s has documented 714 price targets and ratings displayed on 45 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on INSM, Insmed at 08-Sep-2025.

Wall Street Analyst Vamil Divan

Analyst best performing recommendations are on ARAV (ARAVIVE).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $276 was fulfilled within 3 days with a profit of $47.55 (20.81%) receiving and performance score of 69.38.

Average potential price target upside

of $53.12 (43.17%) on KRTX (KARUNA THERAPEUTICS).
of $34.52 (33.46%) on JNJ (JOHNSON & JOHNSON).
of $30.23 (32.83%) on ABBV (ABBVIE).

ABBV AbbVie ACAD ACADIA Pharmaceuticals AGN Allergan plc ALKS Alkermes Plc AXSM Axsome Therapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd EOLS Evolus KRTX Karuna Therapeutics LLY Eli Lilly and Company NBIX Neurocrine Biosciences PFE Pfizer PTLA Portola Pharmaceuticals SAGE Sage Therapeutic STSA Satsuma Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR AIMT Aimmune Therapeutics BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson CABA Cabaletta Bio CFRX ContraFect Corp RVNC Revance The AVTE Aerovate Therapeutics CALT Calliditas Therapeutics CRVS Corvus Pharmaceuticals ESPR Esperion Therapeutics GLPG Galapagos NV ADR GOSS Gossamer Bio IRWD Ironwood Pharmaceuticals KDNY Chinook Therapeutics MRK Merck mpany RLMD Relmada Therapeutics SCYX Scynexis TVTX Travere Therapeutics MGTA Magenta Therapeutics XERS Xeris Pharmaceuticals ANIP ANI Pharmaceuticals INSM Insmed ABSI Absci Corp ALDR Alder BioPharmaceuticals KROS Keros Therapeutics VERA Vera Therapeutics ACRX AcelRx Pharmaceuticals ARAV Aravive ASMB Assembly Biosciences MYGN Myriad Genetics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Geoff Meacham (CITI)